预测直肠癌放化疗急性腹泻:ARISTOTLE III期试验二次分析
本研究基于ARISTOTLE III期试验的589例局部晚期直肠癌患者,利用AI分割的小肠V10Gy、治疗臂、年龄和体能状态构建逻辑回归模型,预测新辅助放化疗后急性腹泻较基线加重≥2级。模型在独立测试集上AUROC为0.71(95%CI 0.58-0.82),并识别出可能从伊立替康增量中获益而无需减量的患者亚群。
要点
- AI分割小肠V10Gy联合治疗臂、年龄和体能状态可预测急性腹泻加重≥2级。
- 模型在独立测试集AUROC为0.71(95%CI 0.58-0.82)。
- 基于预测识别出可个体化调整伊立替康和减量的患者亚群。
核心结论
- 多机构队列模型可作为个体化直肠癌治疗并减轻严重腹泻的策略工具。
研究设计与样本
- ARISTOTLE III期试验二次分析,比较卡培他滨放化疗与卡培他滨-伊立替康放化疗作为局部晚期直肠癌术前治疗。
- 纳入73家机构的589例试验患者。
主要发现
- 预测急性腹泻较基线加重≥2级(ΔG≥2)的平均AUROC为0.71(95%CI 0.58-0.82),基于独立测试数据集。
- 识别出71例(14%)患者可能从加用伊立替康中获益且无需减量即可维持ΔG<2。
- 识别出77例(15%)患者可能从加用伊立替康中获益但需减量以维持ΔG<2。
关键数值与推荐
- 模型使用AI分割的小肠接受至少10 Gy体积(V10Gy)、治疗臂、患者年龄和体能状态。
- 预测目标为急性腹泻毒性较基线加重≥2级(ΔG≥2)。
临床怎么用
- 可利用AI分割小肠V10Gy等参数预测急性腹泻风险,辅助个体化选择伊立替康方案及剂量调整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant chemoradiotherapy is a standard treatment for locally advanced rectal cancer, but acute diarrhoea remains a significant side effect, affecting the completion of chemoradiotherapy treatment. PURPOSE: This study aimed to predict acute diarrhoea after neoadjuvant chemoradiotherapy for rectal cancer and further develop a strategic tool to individualise rectal cancer treatment. MATERIALS AND METHODS: The ARISTOTLE trial is a phase III trial comparing capecitabine chemo-radiotherapy (CRT) versus capecitabine-irinotecan CRT as a pre-operative treatment for locally advanced rectal cancer. We included 589 trial patients across 73 institutions. The volume of the AI-segmented small bowel receiving at least 10 Gy (V10Gy) was used alongside the treatment arm, patient age, and performance status in a logistic regression model to predict a more than 2-grade increase in acute diarrhoea toxicity from baseline (ΔG ≥ 2). Finally, based on the prediction, we identified a sub-cohort of patients for whom a viable dose decrease would result in a reduction of toxicity, and conversely, we also identified individuals for whom adding irinotecan may not cause toxicity. RESULTS: The average mean receiver operating characteristic curve (AUROC) for predicting ΔG ≥ 2 is 0.71 [95 % CI 0.58-0.82] on the independent test dataset. Based on the prediction, we identified 71 patients (14 %) who could potentially benefit from irinotecan addition without a dose decrease to maintain ΔG < 2, and 77 patients (15 %) who could potentially benefit from irinotecan addition but need a dose decrease to maintain ΔG < 2. CONCLUSION: The multi-institutional cohort of 73 centres strengthens the reliability of these findings, demonstrating the model's potential as a strategic tool to individualise rectal cancer treatment while mitigating severe diarrhoea.
引用
- Zhang Y, Brand D, Shen Z, et al. Predicting acute diarrhoea in rectal cancer chemoradiotherapy: Secondary analysis of the phase III ARISTOTLE trial. Radiother Oncol. 2025. PMID: 40618901. doi:10.1016/j.radonc.2025.111032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。